FRIDAY, Oct. 20 (HealthDay News) -- Vulvar intraepithelial neoplasia (VIN), a problem that appears to be on the rise in women in their 40s, should always receive treatment, according to a joint committee opinion issued by the American College of Obstetricians and Gynecologists and the American Society for Colposcopy and Cervical Pathology and published in the November issue of Obstetrics & Gynecology.
According to surveillance data, the incidence of VIN now occurs more than four times the rate it did in the 1970s. The condition is subdivided into usual-type VIN, commonly associated with carcinogenic strains of human papillomavirus, and differentiated VIN, which tends to be associated with vulvar dermatologic conditions.
There are currently no screening recommendations for the prevention of vulvar cancer. VIN is diagnosed visually, and any lesion with pigmentation should be biopsied. Lesions suspected of being cancerous should be surgically removed.
"When occult invasion is not a concern, VIN can be treated with surgical therapy, laser ablation, or medical therapy. After resolution, women should be monitored at six and 12 months and annually thereafter," the authors write.
Abstract
Full Text (subscription or payment may be required)
